217 related articles for article (PubMed ID: 27356907)
1. Understanding the complement-mediated glomerular diseases: focus on membranoproliferative glomerulonephritis and C3 glomerulopathies.
Lionaki S; Gakiopoulou H; Boletis JN
APMIS; 2016 Sep; 124(9):725-35. PubMed ID: 27356907
[TBL] [Abstract][Full Text] [Related]
2. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.
Bomback AS; Appel GB
Nat Rev Nephrol; 2012 Nov; 8(11):634-42. PubMed ID: 23026947
[TBL] [Abstract][Full Text] [Related]
4. Histopathology of MPGN and C3 glomerulopathies.
Cook HT; Pickering MC
Nat Rev Nephrol; 2015 Jan; 11(1):14-22. PubMed ID: 25447133
[TBL] [Abstract][Full Text] [Related]
5. C3 Glomerulopathy.
Riedl M; Thorner P; Licht C
Pediatr Nephrol; 2017 Jan; 32(1):43-57. PubMed ID: 27056062
[TBL] [Abstract][Full Text] [Related]
6. C3 glomerulopathies. A new perspective on glomerular diseases.
Rabasco-Ruiz C; Huerta-Arroyo A; Caro-Espada J; Gutiérrez-Martínez E; Praga-Terente M
Nefrologia; 2013; 33(2):164-70. PubMed ID: 23511752
[TBL] [Abstract][Full Text] [Related]
7. C3 glomerulopathy: what's in a name?
D'Agati VD; Bomback AS
Kidney Int; 2012 Aug; 82(4):379-81. PubMed ID: 22846813
[TBL] [Abstract][Full Text] [Related]
8. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion.
Sethi S; Nester CM; Smith RJ
Kidney Int; 2012 Mar; 81(5):434-41. PubMed ID: 22157657
[TBL] [Abstract][Full Text] [Related]
9. Anti-complement therapy for glomerular diseases.
Bomback AS
Adv Chronic Kidney Dis; 2014 Mar; 21(2):152-8. PubMed ID: 24602464
[TBL] [Abstract][Full Text] [Related]
10. Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis.
Blom AM; Corvillo F; Magda M; Stasiłojć G; Nozal P; Pérez-Valdivia MÁ; Cabello-Chaves V; Rodríguez de Córdoba S; López-Trascasa M; Okrój M
J Clin Immunol; 2016 Jul; 36(5):517-27. PubMed ID: 27146825
[TBL] [Abstract][Full Text] [Related]
11. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification.
Sethi S; Fervenza FC
Semin Nephrol; 2011 Jul; 31(4):341-8. PubMed ID: 21839367
[TBL] [Abstract][Full Text] [Related]
12. [Clinical approach to primary membranoproliferative glomerulonephritis].
Fakhouri F
Nephrol Ther; 2016 Apr; 12 Suppl 1():S65-9. PubMed ID: 26972096
[TBL] [Abstract][Full Text] [Related]
13. Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure.
Ali A; Schlanger L; Nasr SH; Sethi S; Gorbatkin SM
Am J Kidney Dis; 2016 Mar; 67(3):479-82. PubMed ID: 26704376
[TBL] [Abstract][Full Text] [Related]
14. C3 glomerulopathy and current dilemmas.
Ito N; Ohashi R; Nagata M
Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
[TBL] [Abstract][Full Text] [Related]
15. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
Licht C; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809
[TBL] [Abstract][Full Text] [Related]
16. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
Hawfield A; Iskandar SS; Smith RJ
Am J Kidney Dis; 2013 May; 61(5):828-31. PubMed ID: 23391537
[TBL] [Abstract][Full Text] [Related]
17. The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis.
Puri P; Walters GD; Fadia MN; Konia M; Gibson KA; Jiang SH
BMC Nephrol; 2020 Jul; 21(1):265. PubMed ID: 32652953
[TBL] [Abstract][Full Text] [Related]
18. [Progressive renal diseases: recent advances in diagnosis and treatments. Topics: II. Pathophysiology and treatments; 6. Membranoproliferative glomerulonephritis].
Goto S; Narita I
Nihon Naika Gakkai Zasshi; 2013 May; 102(5):1145-51. PubMed ID: 23847979
[No Abstract] [Full Text] [Related]
19. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS).
Sethi S; Fervenza FC
Semin Thromb Hemost; 2014 Jun; 40(4):416-21. PubMed ID: 24799306
[TBL] [Abstract][Full Text] [Related]
20. C3 Glomerulopathy: Pathogenesis and Treatment.
Ahmad SB; Bomback AS
Adv Chronic Kidney Dis; 2020 Mar; 27(2):104-110. PubMed ID: 32553242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
